A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease
Non-erosive Reflux Disease, Erosive Esophagitis
About this trial
This is an interventional treatment trial for Non-erosive Reflux Disease
Eligibility Criteria
Inclusion Criteria: Have completed the BLI5100-301 or BLI5100-302 study with no serious AE (SAE) related to study drug and no major Protocol Deviations; Able to understand and comply with the protocol requirements; Willing and able to provide written informed consent at Screening; Is a female of non-childbearing potential, or If a female of childbearing potential, agrees to use an acceptable form of birth control from the Screening Visit until 30 days after the last dose of study drug; If a male, agrees to use an acceptable form of birth control from the Screening Visit until 3 months after the last dose of study drug; If a male, agrees to abstain from sperm donation through 3 months after administration of the last dose of study drug; Have documented healed EE (BLI5100-301 study patients only). Exclusion Criteria: History of alcoholism, or substance abuse/addiction in the year before enrollment in the BLI5100-301 and BLI5100-302 studies; Note: Patients on prescribed opioids are eligible to participate if they have been on a stable dose for >3 months prior to Screening. Note: Patients on prescribed opioids are eligible to participate if they have been on a stable dose for the duration of the BLI5100-301 and BLI5100-302 studies. Presence of manic-depression, anxiety disorder, panic disorder, somatoform disorder, personality disorder, or other psychological disorder; Current use of antipsychotics, antidepressants, anxiolytics, or prescription sleeping medications, with the exception of a stable dose for the duration of the BLI5100-301 and BLI5100-302 studies; Requirement of persistent use of non-steroidal anti-inflammatory drugs (NSAIDs) during the course of the study; o Note: Low-dose (≤100 mg/day) aspirin is allowed provided that it has been used for prophylaxis prior to study participation. If a female, is pregnant, breastfeeding, or planning to become pregnant during the study or within 30 days after the last dose of study drug; Abnormal laboratory results with clinical relevance at Screening as follows: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase level of ≥2 × upper limit of normal (ULN); Total bilirubin level of ≥2 × ULN, unless Gilbert's syndrome is confirmed when direct bilirubin is ≤0.3 mg/dL; Estimated glomerular filtration rate <30 mL/min. Abnormal ECG of clinical significance; Involvement in another clinical study (other than BLI5100-301 and BLI5100-302 studies) within 4 weeks of initiation of study drug; Any other clinically relevant condition that would confound study endpoints or adversely affect patient compliance with the study procedures in the medical judgment of the Investigator or Medical Monitor based on previous medical history or findings on Screening assessments.
Sites / Locations
- Research Site 24
- Research Site 62
- Research Site 94
- Research Site 10
- Research Site 72
- Research Site 13
- Research Site 41
- Research Site 91
- Research Site 23
- Research Site 42
- Research Site 38
- Research Site 43
- Research Site 17
- Research Site 90
- Research Site 11
- Research Site 46
- Research Site 59
- Research Site 01
- Research Site 02
- Research Site 45
- Research Site 12
- Research Site 48
- Research Site 06
- Research Site 64
- Research Site 35
- Research Site 07
- Research Site 28
- Research Site 40
- Research Site 20
- Research Site 60
- Research Site 103
- Research Site 100
- Research Site 98
- Research Site 29
- Research Site 32
- Research Site 22
- Research Site 26
- Research Site 65
- Research Site 16
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
BLI5100 Low Dose
BLI5100 High Dose
Patients will take BLI5100 Low Dose once daily, orally, for up to 29 weeks.
Patients will take BLI5100 High Dose once daily, orally, for up to 29 weeks.